Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide. The acquisition...
PHARMASEAL’s Engility® platform fights off competition to be selected by award-winning US Medical Device company
PHARMASEAL, a provider of clinical trial management and governance solutions, announced today that it has secured its first Medical Device customer – an award-winning US-based company providing ultrasound technology. The Engility® Trial Management Platform was chosen following review of several clinical trial management systems (CTMS). Engility was selected for its combined...
SureScreen Diagnostics to supply 20 million rapid lateral flow tests to Government
New contract secured with Derby-based manufacturer for validated lateral flow antigen tests, ensuring supply for the UK over coming months. New tests will support the government’s drive to deliver rapid testing to those without symptoms to break chains of transmission New tests can return results in 30 minutes, and are...
Cresco celebrate winning more than £6million in funding so far in 2021
During these difficult times when good news seems to be in short supply, we thought it would be nice to share with you some positivity that we, as a company, have recently experienced. It has not been the start to 2021 that any of us envisaged, but we do have...
NEW FUNDING FOR XCAM SPACE PROJECT TO HELP SOLVE PROBLEMS ON EARTH
Through the UK Space Agency, Government is giving a cash injection to five projects specifically designed to bring together UK business expertise with universities to help build space solutions to global problems, on UK soil. The University of Leicester is to receive research funding to support XCAM for one of...
Digital Technologies: an opportunity to make healthcare more inclusive
2020 saw a huge increase in the adoption of digital technologies within modern healthcare economies. From the adoption of video-based triage and GP-to-patient consultations within primary care, to remote monitoring for shielding and vulnerable patients, as well as those discharged early from hospital – both within their own homes and...
Early-stage life science ventures invited to apply for specialist support ahead of investment rounds
BioCity, the pioneering life science incubator and business collective, Innovate UK, NIHR and NHS England and NHS Improvement’s SBRI Healthcare programme, today announced a new partnership to support early-stage life science ventures within the UK to get investment ready. Working in collaboration, the organisations are launching a new Investment Readiness...
Double promotion at V Formation
Nottingham marketing and PR agency, V Formation, has promoted two members of its team. The agency’s Leah Bradley is promoted to Senior Marketing Consultant and Lucy Wharton to Senior PR Executive. A specialist in marketing strategy development, implementation, communications and planning, Leah has been with V Formation since 2016. With...
The Midlands is delivering £90m of COVID research to support the nation’s fight against COVID-19
A new report - Mobilising Research Excellence in the Midlands to Tackle COVID-19 - published today (Friday, January 15 2021) reveals that the Midlands has moved swiftly to apply its wealth of capability in its hospitals, universities and businesses to deliver £90m of research to support regional, national and global...
Reach Separations launches European expansion plans with purification alliance with NovAliX
Nottingham-based purification specialists Reach Separations and French drug discovery contract research organisation (CRO), NovAliX, have entered into a unique alliance to develop supercritical fluid chromatography (SFC) capabilities at the NovAliX facility near Strasbourg. Formed in support of Reach Separations’ strategy to grow its European presence, and in response to a...